Navigation Links
Exelixis in Medical News

Reminder: Exelixis Announces December 10 Webcast of Its Analyst and Investor Briefing in Conjunction with The American Society Of Hematology 48th Annual Meeting

SOUTH SAN FRANCISCO, Calif., Dec. 6 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL ) announced today that that it will hold an analyst and investor briefing in conjunction with The American Society of Hematology 48th Annual Meeting from 8:00 p.m. to 9:00 p.m. ET on Monday, December 10...

Exelixis Reports Phase 1 and Phase 2 Data For XL647 at ASCO

...d Analyst Briefing at ASCO, Monday, June 2, 6 pm exelixis will host an investor and analyst briefing on Mond...ck Place (Regency C&D - 2nd Floor). At this event, exelixis will provide a review of its data presented at ASC...ounds in phase 2 and phase 1 clinical development. exelixis has established strategic corporate alliances with...

QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes

... Ltd. (TSE: 4523.T) Encysive Pharmaceuticals Inc. (Nasdaq: ENCY ) Enzo Biochem Inc. (NYSE: ENZ ) ENZON PHARMACEUTICALS INC. (Nasdaq: ENZN ) exelixis Inc. (Nasdaq: EXEL ) Flamel Technologies (Nasdaq: FLML ) Illumina Inc. (Nasdaq: ILMN ) Incyte Corporation (Nasdaq: INCY ) Integra LifeScie...

Exelixis Announces March 19 Webcast of Presentation at the Lehman Brothers Annual Global Healthcare Conference

...bcast and may be accessed in the Event Calendar page under Investors on the exelixis website at http://www.exelixis.com . About Exelixis Exelixis, Inc. is ...udes investigational compounds in phase 2 and phase 1 clinical development. exelixis has established strategic corporate alliances with major pharmaceutical and...

Exelixis Announces December 10 Webcast of Its Analyst and Investor Briefing in Conjunction With The American Society of Hematology 48th Annual Meeting

...rrently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development for cancer and renal disease. exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb C...

Exelixis to Receive Milestone Payment From Bristol-Myers Squibb for Achievement of Liver X Receptor Agonist Development Milestone

...her investigating that potential in this trial." exelixis and Bristol-Myers Squibb established their joint L...l period of two years. The collaboration calls for exelixis and Bristol-Myers Squibb to jointly identify drug ...activities for such compounds. At time of signing, exelixis received a $17.5 million upfront payment and a com...

Exelixis Announces November 6 Webcast of Presentation at the CIBC World Markets 18th Annual Healthcare Conference

... in the Event Calendar page under Investors on the exelixis website at http://www.exelixis.com . About exelixis Exelixis, Inc. is a development-stage biotechnolo...clinical development for cancer and renal disease. exelixis has established strategic corporate alliances with...

Exelixis Announces October 10 Webcast of Presentation at the 2007 Bio InvestorForum Conference

... in the Event Calendar page under Investors on the exelixis website at http://www.exelixis.com . About exelixis Exelixis, Inc. is a development-stage biotechnolo...clinical development for cancer and renal disease. exelixis has established strategic corporate alliances with...

Exelixis Announces September 18 Webcast of Presentation at the Bank of America 2007 Investment Conference

... in the Event Calendar page under Investors on the exelixis website at http://www.exelixis.com . About exelixis Exelixis, Inc. is a development-stage biotechnolo...clinical development for cancer and renal disease. exelixis has established strategic corporate alliances with...

Exelixis Commences Public Offering of Common Stock

... effective automatic shelf registration statement. exelixis will also grant the underwriter a 30-day option to...nder the securities laws of any such state. About exelixis Exelixis, Inc. is a development-stage biotechnolo...he public offering. There can be no assurance that exelixis will complete the offering of the common stock on ...
Exelixis in Medical Technology

Six Abstracts Featuring Exelixis Compounds Accepted At ASCO Conference

- Phase I data from XL880, Phase II data from XL999 studies scheduled for presentation during oral, poster sessions - SOUTH SAN FRANCISCO, May 30, 2007 /PRNewswire-FirstCall/ -- Exelixis, Inc. announced today that data from clinical trials of the company's investigational compounds XL880 and XL999...

Exelixis Presents Clinical Data Supporting the Safety and Initial Clinical Activity of XL228 in Chronic and Acute Leukemia

...ounds in phase 2 and phase 1 clinical development. exelixis has established strategic corporate alliances with...mstances on which any such statements are based. exelixis and the exelixis logo are registered U.S. trademarks. ...

Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO

...d Analyst Briefing at ASCO, Monday, June 2, 6 pm exelixis will host an investor and analyst briefing on Mond...ck Place (Regency C&D - 2nd Floor). At this event, exelixis will provide a review of its data presented at ASC...ounds in phase 2 and phase 1 clinical development. exelixis has established strategic corporate alliances with...

Exelixis Reports Positive Clinical Pharmacodynamics Data for PI3K/mTOR Inhibitor XL765 at ASCO

...Analyst Briefing at ASCO, Monday, June 2, 6 p.m. exelixis will host an investor and analyst briefing on Mond...ck Place (Regency C&D - 2nd Floor). At this event, exelixis will provide a review of its data presented at ASC...ounds in phase 2 and phase 1 clinical development. exelixis has established strategic corporate alliances with...

Exelixis Announces First Quarter 2008 Financial Results

...7 and XL880*). * The technology transfer by exelixis to GlaxoSmithKline (GSK) in connection with GSK...ounds in phase 2 and phase 1 clinical development. exelixis has established strategic corporate alliances with...nces on which any such statements are based. exelixis and the...

GSK Does Not Option XL784 for Further Development

...784 for further development and commercialization. exelixis previously announced that XL784 failed to meet its...ns to choose XL784. As a result of GSK's decision, exelixis has the right to develop and commercialize XL784 e...clinical development for cancer and renal disease. exelixis has established strategic corporate alliances with...

Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer

...s in phase 2 and phase 1 clinical development for cancer and renal disease. exelixis has established strategic corporate alliances with major pharmaceutical and...07 and Exelixis' other filings with the Securities and Exchange Commission. exelixis expressly disclaims any duty, obligation or undertaking to release publicly...

Exelixis Presents Encouraging Phase 1 Data For XL019, A Novel Selective Inhibitor of JAK2

...rrently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development for cancer and renal disease. exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb C...

Phase 2 Trial Results for Exelixis' XL784 Presented at the 2007 American Society of Nephrology Conference

... is the first small molecule compound developed by exelixis using its proprietary drug discovery engine. The c...active safety and pharmacokinetic profiles. About exelixis Exelixis, Inc. is a development-stage biotechnolo...clinical development for cancer and renal disease. exelixis has established strategic corporate alliances with...

Interim Phase 2 Data for Exelixis' XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer

...evelopment and commercialization agreement between exelixis and GlaxoSmithKline (GSK), GSK has the option, aft...a, gastric cancer and head and neck cancer. About exelixis Exelixis, Inc. is a development-stage biotechnolo...clinical development for cancer and renal disease. exelixis has established strategic corporate alliances with...
Exelixis in Biological Technology

REMINDER: Exelixis Will Webcast Its June 2 Investor and Analyst Briefing at ASCO

Seven Abstracts Accepted for Presentation at ASCO SOUTH SAN FRANCISCO, Calif., May 28 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL ) will hold an investor and analyst briefing in conjunction with the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) ...

Seven Abstracts Featuring Exelixis Compounds Accepted for Presentation at 2008 ASCO Annual Meeting

Two oral presentations, two poster discussion presentations, three poster presentations SOUTH SAN FRANCISCO, Calif., March 31 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL ) announced today that data from clinical trials of the company's investigational com...

Option to Develop Exelixis Compound Exercised By Genentech

SOUTH SAN FRANCISCO, Calif., March 14 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL ) today announced that Genentech, Inc. has exercised its option to further develop and commercialize Exelixis' compound XL518, a selective and potent inhibitor of MEK, which is currently in a phase 1 ...

Reminder: Exelixis Announces December 5 Webcast of Its Third Annual R&D Day

SOUTH SAN FRANCISCO, Calif., Nov. 28 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL ) announced today that it will hold its Third Annual R&D Day on Wednesday, December 5, 2007 from 10:00 a.m. ET / 7:00 a.m. PT to 2:00 p.m. ET / 11:00 a.m. PT in New York. The company will discuss updat...

Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation

INDIANAPOLIS and SOUTH SAN FRANCISCO, Calif., Sept. 4 /PRNewswire-FirstCall/ -- Dow AgroSciences LLC, a wholly owned subsidiary of The Dow Chemical Company (NYSE: DOW ), and Exelixis Plant Sciences, a wholly owned subsidiary of Exelixis, Inc. (Nasdaq: EXEL ), announced today that the compani...

Sanofi-aventis Announces Second Quarter 2009 Results

... in triple negative breast cancer; license and collaboration agreement with exelixis Exploring external growth opportunities : significant boost to our ...r both of these products, which were developed by the biotechnology company exelixis SAR 407899, a rho-kinase inhibitor, entered Phase II in...

iZumi Bio Appoints Dr. Corey Goodman to Board of Directors and Scientific Advisory Board

...is from 2001 until 2007, when the company merged with Evotec. He has advised numerous biotechnology companies, and co-founded two companies, including exelixis and Renovis. Dr. Goodman was a professor at Stanford University and the University of California, Berkeley for over two decades, and is curr...

Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration

... exelixis Generated 10 IND Compounds and Received over $235 ... will be limited to the compounds selected by GSK. exelixis will have the right to perform additional discover...ship of the compounds in our pipeline." To date, exelixis has received approximately $235 million from GSK, ...

Exelixis Announces June 25 Webcast of Presentation at the Piper Jaffray Europe Conference

...bcast and may be accessed in the Event Calendar page under Investors on the exelixis website at http://www.exelixis.com . About Exelixis Exelixis, Inc. is ...udes investigational compounds in phase 2 and phase 1 clinical development. exelixis has established strategic corporate alliances with major pharmaceutical and...

Mergent, Inc. Announces Quarterly Rebalancing of HealthShares(TM) Indexes

...APUTICS GROUP PLC (London Main Market, U.K.: AKT) exelixis INC. (NASDAQ: EXEL ) HUMAN GENOME SCIENCES INC. ...NYSE: CVD ) DAINIPPON SUMITOMO (Tokyo SE: 4506) exelixis INC (NASDAQ: EXEL ) FRESENIUS SE (Frankfurt, Ger...: BGC) COUGAR BIOTECHNOLOGY INC (NASDAQ: CGRB ) exelixis INC (NASDAQ: EXEL ) LIGAND PHARMACEUTICALS INC (...
Other Tags
(Date:10/22/2014)... 2014 On Saturday, October 25, 2014, the ... family health and fitness fair ¡Vive tu vida! Get Up! ... good nutrition for better health and wellness for people of ... and open to the public, will be held at Dean ... am to 1:00 pm. , “¡Vive tu Vida! Get ...
(Date:10/22/2014)... 22, 2014 Medical Solutions ... is happy to announce that our co-founder and ... Industry Analysts’ Staffing 100 for 2014. Anderson was ... most influential people in the staffing industry,” in ... the 13th-largest healthcare staffing company in the U.S., ...
(Date:10/22/2014)... 2014 For Dr. Iris Hunter, a job ... an extension of her life’s mission. Her extensive experience in ... owner of FirstLight HomeCare, make it clear that Hunter’s mission ... that my work makes a difference in the lives of ... so after much research, I felt ready to start on ...
(Date:10/22/2014)... TUESDAY, Oct. 21, 2014 (HealthDay News) -- The ... passengers arriving from Ebola-affected nations of West Africa ... screen them for infection with the virus. ... Jeh Johnson noted that 94 percent of air ... land at one of these five airports -- ...
(Date:10/22/2014)... Va. (PRWEB) October 22, 2014 ... Innovation , which is dedicated to distribute health ... of healthcare delivery worldwide announced the development of ... which patients expect when receiving healthcare. These are ... for patient-centered care: “providing care that is respectful ...
Breaking Medicine News(10 mins):Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 4Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 2Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 3Health News:Dr. Iris Hunter to Host Grand Opening of FirstLight HomeCare Tomorrow 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 3Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2
(Date:10/16/2014)... and Mary,s Virginia Institute of Marine Science have ... Protection Agency to identify the streams and wetlands ... tools to help local governments and citizens conserve ... on a dataset of tidal-marsh observations first gathered ... this historical baseline can today,s researchers accurately map ...
(Date:10/16/2014)... – Post-menopausal women experienced improvements in vaginal atrophy, ... genital bleeding, after 12 weeks of daily 10 ... germ-based nutritional supplement previously shown to help relieve ... pilot study reported in a poster at the ... , "These data documented improved vaginal epithelium, ...
(Date:10/15/2014)... Gutenberg University Mainz (JGU) as a full member, ... maintain a significant nationwide standing in the field ... Johannes Gutenberg University Mainz as a full member ... national and international competition for the best minds ... be proud that Mainz University has been recognized ...
Breaking Biology News(10 mins):EPA grant will help localities conserve headwater wetlands 2EPA grant will help localities conserve headwater wetlands 3S-equol supplements associated with improved measures of reproductive health in postmenopausal women 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3
Other Contents